IRIS
PELUSO, ANNA LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 111
EU - Europa 79
NA - Nord America 70
SA - Sud America 4
Totale 264
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 70
US - Stati Uniti d'America 70
IL - Israele 60
SG - Singapore 47
DE - Germania 6
BR - Brasile 4
ID - Indonesia 2
BD - Bangladesh 1
JP - Giappone 1
NL - Olanda 1
PL - Polonia 1
UA - Ucraina 1
Totale 264
Salva come PNG Salva come JPEG
Città #
Chicago 64
Rome 60
Tel Aviv 60
Singapore 47
Milan 4
Naples 2
Belo Horizonte 1
Cape Girardeau 1
Curitiba 1
Dhaka 1
Diamantino 1
Dębica 1
Itajaí 1
Rimini 1
Tokyo 1
Totale 246
Salva come PNG Salva come JPEG
Nome #
Acute and Chronic Ph+ leukemias: differential leukemogenesis pathways translate into different clinical needs 8
First case of KIT Ser715del and Jak2 Val617Val mutation in systemic mastocytosis with associated essential thrombocythemia 7
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 7
First case of S716del mutation in the cKIT gene and V617V mutation in Jak2 gene in a patient affected by essential thrombocytopenia associated to systemic mastocytosis 6
Increasing BCR-.ABL expression levels and/or occurrence of ABL point mutations not always predict resistance to Imatinib Mesylate in BCR-ABL positive Acute Lymphoblastic Leukemia 6
Unravelling the Mechanism of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia: a Proteomic Approach 6
Clinical relevance in Chronic Myeloid Leukemia of deletion and insertion events in tyrosine kynase domain of BCR-ABL 6
Heat Shock Protein 90 (HSP90) regulates the expression of preferentially Expressed Antigen of Melanoma (PRAME) in cell lines derived from patients with Chronic Myeloid Leukemia 6
A particular mutational status in a Chronic Myeloid Leukemia patient treated with different tyrosine-Kinase inhibitors 6
Clinical outcome of Chronic Myeloid Leukemia (CML) patients with deletion and Insertion events (DI) in the Tyrosine Kinase Domain of Bcr-Abl 6
Deletion and insertion events in tyrosine Kinase domain of BCR-ABL is a common phenomenon in Chronic Myeloid Leukemia 6
Biochimica ematologica in Biochimica del plasma e sistema ematopoietico 5
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 5
Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis 5
Frequencies of cKIT mutations detected in patients with Acute Myeloid Leukemia (AML) characterized by Core Binding Factor (CBF) rearrangements 5
Clonal evolution in a case of hepatosplenic T cell lymphoma 5
Use of nodulation pattern, stress tolerance, nodC gene amplification, RAPD-PCR and RFLP-16S rDNA analysis to discriminate genotypes of Rhizobium leguminosarum biovar viciae 5
Decrease level of SHP1 provides an additive survival advantage to Philadelphia chromosome-positive (Ph+) cells derived from patients with chronic myeloid leukemia (CML) and account for resistance to Imatinib (Ima) treatment 5
Attivazione di una immunità specifica per PRAME mediante l'utilizzo di una libreria peptidica in pazienti affetti da patologie ematologiche 5
La proteina SHP-1 è implicata nella resistenza al trattamenti con Imatinib (Ima) in pazienti affetti da leucemia mieloide cronica (LMC) 5
Highly Sensitive Detection of BCR-ABL Kinase Domain Mutations in CML patients by an Ultra-Deep Sequencing Approach 5
Primo caso di trombocitemia essenziale (TE) associate a mastocitosi ossea con mutazione S715del del gene c-KIT e V616V del gene JAK2 5
The dynamics of ABL mutations onset in Ph+ Acute Lymphoblastic Leukemia treated with Imatinib Mesylate 5
Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma 5
Characterization of proteins involved in the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia 5
Characterization of proteins involved in the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia 5
High-avidity cytotoxic lymphocytes specific for a new peotide derived from Preferentially expressed Antigen of Melanoma (PRAME) can target leukemia precursor cells 5
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 5
Immunoglobulin heavy and light chains and T-cell receptor beta and gamma chains PCR assessment on cytological samples. A study comparing FTA cards and cryopreserved lymph node fine-needle cytology 5
Risorse genetiche di organismi utili per il miglioramento di specie di interesse agrario e per un'agricoltura sostenibile 5
Diversity of Rhizobium leguminosa rum biovar viciae strains nodulating wild and crop legumes in central-southern Italy 5
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients 5
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 5
Effectiveness of interferon alpha therapy in essential thrombocythemia 5
The expression of shp-1 andSHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 5
Clinical relevance in Chronic Myeloid Leukemia of deletion and insertion events in the tyrosine Kinase domain of BCR-ABL 5
Evaluation of proteolytic, lipolytic and decarboxylase activity of extremely halophilic bacteria occurring in ripening of salt anchovies 5
Ligh chains expression of lymphoid infiltrate in fine-needle cytology of Hashimoto's Thyroiditis 5
Caratterizzazione dei ceppi di Rhizobium spp. Simbionti di leguminose selvatiche e coltivate del climax mediterraneo 5
Induction of preferentially expressed antigen of melanoma (PRAME)-specific immunity by PRAME-overlapping pentadecapeptides in patients with hematologic malignancies, including chronic myelogenous leukemia 5
Cytopathology diagnosis of the thyroidal nodule: a review 5
cKIT mutations frequency detected in patients with Acute Myeloid Leukemia (AML) characterized by Core Binding Factor (CBF) rearrangement 5
Reduced levels of SHP1 provides an additive survival advantage to the Ph+ cells of CML patients and may account for resistance to Ima treatment 5
Flow cytometric immunophenotypic and molecular profiles and follow-up in a case of gamma-delta hepatosplenic T-cell Lymphoma 5
Evalution of proteolytic, lipolytic and decarboxylase activity of extremely halophilic bacteria occurring in ripening of salt anchovies 5
Light chains expression of lymphoid infiltrate in fine-needle cytology of Hashimoto's Thyroiditis 5
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukaemia 5
Mesenchymal stem cell (MSC) derived from bone marrow (BM) of patients with Chronic Myelogenous Leukemia protect Ph+ leukemic cells from TKI induced apoptosis 5
Induction of preferentially expressed antigen of melanoma (PRAME)-specific immunity by PRAME-overlapping pentadecapeptides in patients with hematologic malignancies. Including chronic myelogenous leukemia 5
The constitutive activated V617F Janus Kinase 2 (JAK2) induces centrosome abnormalities 5
The activity of tyrosine Kinase inhibitors on T-cell proliferation and activation 5
SHP1 expression accounts for resistance to Imatinib treatment in Philadelphia chromosome-positive cells derived from patients with Chronic Myeloid Leukemia 5
Unravelling the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia: a proteomic approach 5
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma 5
Clinical relevance in chronic myeloid leukemia of deletion and insertion events in the tyrosine Kinase domain of BCR-ABL 5
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pre-treatment Predictor of Major Molecular Response Achievement in CML Patients 5
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 5
Characterization of Rhizobium spp.strains symbionts of wild and cultivated legumes of the Mediterranean climax 4
Increasing BCR-ABL expression levels and/or occurrence of ABL point mutations not always predict resistance to Imatinib Mesylate in BCR-ABL positive Acute Lymphoblastic Leukemia 4
The dynamics of ABL mutations onset in PH+ Acute Lymphoblastic Leukemia treated with Imatinib Mesylate 4
Decreased level of SHP-1 provides an additive survival advantage to Philadelphia Chromosome-positive (Ph+) cells derived from patients with Chronic Myeloid Leukemia (CML) and account for resistance to Imatinib (Ima) treatment 4
Reduced levels of SHP1 provides an additive serviva advantage to the PH- cells of CML patients and may account for resistance to IMA treatment 4
La proteina SHP-1 è implicata nella resistenza al trattamenti con Imatinib (Ima) in pazienti affetti da leucemia mieloide cronica (LMC) 4
The A1059E mutation in Jak2 gene was detected in patients with Idiopathic Erithrocytosis secondary to Acute Lymphoblastic Leukemia 4
Totale 328
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.953
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.953
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025328 0 0 0 64 2 4 5 126 14 0 110 3
Totale 328